- Trials with a EudraCT protocol (256)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
256 result(s) found for: Entry inhibitors.
Displaying page 7 of 13.
EudraCT Number: 2013-003250-25 | Sponsor Protocol Number: B1871039 | Start Date*: 2014-06-24 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A Phase 4 Safety and Efficacy Study of Bosutinib (Bosulif®) in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One or More Tyrosine Kinase Inhibitors | |||||||||||||
Medical condition: Philadelphia Chromosome Positive Chronic Myeloid Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DE (Prematurely Ended) IT (Completed) BE (Completed) NL (Completed) ES (Completed) AT (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002667-33 | Sponsor Protocol Number: 24051 | Start Date*: 2007-06-18 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Phase I/II study on induction chemotherapy followed by chemoradiation with or without lapatinib, a dual EGFR/ErbB2 kinase inhibitor, in patients with locally advanced resectable larynx and hypophar... | |||||||||||||
Medical condition: locally advanced resectable larynx and hypopharynx squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006275-21 | Sponsor Protocol Number: RRK3199 | Start Date*: 2007-01-10 | |||||||||||
Sponsor Name:University Hospital Birmingham NHS Foundation Trust | |||||||||||||
Full Title: A Randomised, Pragmatic, Open-label study of Adalimumab versus Etanercept for Rheumatoid Arthritis. | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002178-22 | Sponsor Protocol Number: 11-AVR-130 | Start Date*: 2011-12-26 | |||||||||||
Sponsor Name:Avanir Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding Study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in ... | |||||||||||||
Medical condition: Central Neuropathic Pain in Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) CZ (Completed) PL (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022403-22 | Sponsor Protocol Number: CLCI699C2201 | Start Date*: 2011-07-04 | |||||||||||
Sponsor Name:NOVARTIS FARMA | |||||||||||||
Full Title: A proof-of concept, open-label, forced titration, multicenter study to assess the safety/tolerability and efficacy of 10-weeks treatment of LCI699 in patients with Cushing’s disease | |||||||||||||
Medical condition: Cushing's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012529-12 | Sponsor Protocol Number: 0827703 | Start Date*: 2009-06-10 | |||||||||||
Sponsor Name:CHU de Toulouse | |||||||||||||
Full Title: A randomised, REQUIP® IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP®CR on abnormal daytime somnolence in patients with Parkinson’s Disease | |||||||||||||
Medical condition: parkinson's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003984-23 | Sponsor Protocol Number: BOC-HIV | Start Date*: 2013-04-19 | ||||||||||||||||
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||||||||||||||||||
Full Title: A phase III open label study to evaluate safety and efficacy of Boceprevir-response guided therapy in controlled HIV patients with chronic hepatitis C genotype 1 infection who failed previously to ... | ||||||||||||||||||
Medical condition: HCV and HIV seropositive coinfection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006412-29 | Sponsor Protocol Number: 3144A1-203-WW | Start Date*: 2007-10-18 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase 1 / 2 Study of HKI-272 in combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer | |||||||||||||
Medical condition: Metastatic breast cancer remains incurable and represents an area of unmet medical need globally. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) activat... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005659-19 | Sponsor Protocol Number: RG_14-287 | Start Date*: 2015-10-21 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed therapy with corticosteroids | |||||||||||||
Medical condition: Chronic Graft versus Host Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001737-15 | Sponsor Protocol Number: D1449C00009 | Start Date*: 2005-07-18 | |||||||||||
Sponsor Name:NV AstraZeneca SA | |||||||||||||
Full Title: An open-label, non-comparative, multi-centre, phase II prospective trial to assess the efficacy of Quetiapine fumarate augmentation of selective serotonin reuptake inhibitors (SSRIs) in SSRI-resist... | |||||||||||||
Medical condition: The medical condition being treated by this protocol is single or recurrent major depressive disorder (MDD), not responding to at least one adequate SSRI treatment, however, the patients being trea... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002361-31 | Sponsor Protocol Number: GS-US-228-0101 | Start Date*: 2008-09-09 | |||||||||||
Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Activity of GS 9450 in Adults with Non-Alcoholic Steatohe... | |||||||||||||
Medical condition: Non-Alcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002147-34 | Sponsor Protocol Number: AZT-001 | Start Date*: 2016-01-21 | |||||||||||
Sponsor Name:AZTherapies, Inc. | |||||||||||||
Full Title: A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease. | |||||||||||||
Medical condition: Early stage of Alzheimer's Disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006716-30 | Sponsor Protocol Number: 128/2006/O/Sper | Start Date*: 2006-12-19 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: Randomized, controlled, multicentric trial to evaluate efficacy and safety of the switch from a LPV/r based therapy to an ATV/r or a NVP based treatment in association with ABC/3TC, in HIV patient ... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003798-82 | Sponsor Protocol Number: R1578 | Start Date*: 2014-01-29 | |||||||||||
Sponsor Name:Hull & East Yorkshire Hospitals NHS Trust | |||||||||||||
Full Title: Multi-centre Randomised Controlled Trial of Angiotensin Converting Enzyme inhibitor (ACEi) / Angiotensin Receptor Blocker (ARB) withdrawal in advanced renal disease; The STOP-ACEi Trial | |||||||||||||
Medical condition: Progressive, advanced (stage 4 or 5) chronic kidney disease (CKD). NB. There was not an appropriate therapeutic area in the drop down menu in E1-1. Have selected 'Male diseases of the urinary and... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001596-20 | Sponsor Protocol Number: HelPIT-730-163-2018 | Start Date*: 2018-12-21 |
Sponsor Name:Helixor Heilmittel GmbH | ||
Full Title: Influence of a Helixor® P infusion therapy on the Cancer-related Fatigue (CrF) of female patients with advanced breast cancer or female or male patients with NSCLC during oncological standard thera... | ||
Medical condition: advanced breast cancer in female patients or advanced non-small cell lung cancer (NSCLC) in female or male patients during oncological standard therapy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003564-24 | Sponsor Protocol Number: JAB-3312-1003 | Start Date*: 2023-05-05 | |||||||||||
Sponsor Name:Jacobio Pharmaceuticals Co., Ltd. | |||||||||||||
Full Title: A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult P... | |||||||||||||
Medical condition: Advanced Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003877-91 | Sponsor Protocol Number: TOLERA | Start Date*: 2019-06-13 | |||||||||||
Sponsor Name:Universitätsklinikum Erlangen | |||||||||||||
Full Title: Sequential B cell/T cell therapy to re-induce humoral immune tolerance in ACPA-positive Rheumatoid Arthritis (TOLERA): a prospective randomized controlled open-label single-centre clinical trial in... | |||||||||||||
Medical condition: Active rheumatoid arthritis with ACPA antibodies failing methotrexate | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003311-26 | Sponsor Protocol Number: 77839 | Start Date*: 2021-11-18 |
Sponsor Name:Prinses Máxima Centrum | ||
Full Title: DAVINCY trial: optimal Duration of (fos)aprepitant prophylaxis for nausea and Vomiting INduced by ChemotherapY in children: a double-blind placebo-controlled crossover randomized phase III trial’ | ||
Medical condition: prolonged anti emetic treatment | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002530-20 | Sponsor Protocol Number: GEM-1802 | Start Date*: 2019-03-12 | ||||||||||||||||
Sponsor Name:Grupo Español Multidisciplinar de Melanoma | ||||||||||||||||||
Full Title: Multicentric phase II clinical trial to evaluate the activity of encorafenib and binimetinib before local treatment in patients with BRAF mutated melanoma with metastasis to the brain. | ||||||||||||||||||
Medical condition: BRAF mutant melanoma metastatic to the brain | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001689-34 | Sponsor Protocol Number: M10-030 | Start Date*: 2008-04-24 | ||||||||||||||||
Sponsor Name:Abbott GmbH & Co. KG | ||||||||||||||||||
Full Title: The PRIMO Study: Paricalcitol Capsules benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 3B/4. Estudio Primo: Beneficios de Paricalcitol cápsulas sob... | ||||||||||||||||||
Medical condition: Stage 3B/4 chronic kidney disease (CKD) in subjects who have left ventricular hypertrophy (LVH). Insuficiencia renal crónica en estadío 3B/4 en sujetos con hipertrofia ventricular izquierda. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) CZ (Completed) GB (Completed) IT (Completed) DE (Completed) SE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
